HemoBioTech Chairman & CEO Arthur Bollon, Ph.D., to Present at the Bio International Convention in San Diego, CA

DALLAS--(BUSINESS WIRE)--Arthur Bollon, Ph.D., chairman & CEO of HemoBioTech, Inc. (OTCBB: HMBT.OB), will present at the 2008 Biotechnology Industry Organization (BIO) International Convention in San Diego, CA tomorrow, June 19, 2008. Dr. Bollon’s presentation is scheduled for 1:00 PM PDT.

The Biotechnology Industry Organization selected HemoBioTech to be among the companies to present at the BIO 2008 Business Forum. The BIO Forum offers a platform for partnering between biotechnology and pharmaceutical companies and the investment community.

Dr. Bollon will make a presentation of the company’s proprietary HemoTech blood substitute technology as well as the Orthogonal purification technology for clearance of viruses and prions during the production of animal and human derived products for use in humans.

“It is my esteemed privilege to present at the business forum,” said Dr. Bollon, chairman & CEO of HemoBioTech. “This function gathers industry luminaries and noteworthy academics from across the globe. Being afforded the opportunity to present our story to such an audience is key to furthering the company.”

About the 2008 BIO International Convention

The 2008 BIO International Convention, hosted by the Biotechnology Industry Organization, reflects the growing promise of biotechnology and innovative solutions to help heal, fuel and feed the world and provide a cleaner environment. The convention will feature keynotes from industry and global leaders, more than 175 breakout sessions, business partnering meetings, and numerous networking events. The convention also includes more than 200,000 square feet of exhibitions showcasing the latest advancements in biotechnology alongside an array of potential partners, service providers, and state and international delegations.

The BIO International Convention is where the global biotechnology community comes together to address key issues and make the vital connections needed to drive future innovations aimed at improving global health and overall quality of life in all regions of the world. BIO anticipates more than 20,000 industry leaders, government officials, and others will attend the convention. In 2007, the convention attracted 22,366 attendees and exhibitors with approximately one-third from countries outside the U.S. The 2007 event also hosted more than 300 domestic and international public officials including seven U.S. governors.

The BIO International Convention is the world’s largest gathering of the biotechnology industry attended by more than 20,000 participants. The convention is a blend of international and domestic executives and management from research, business, academic, and investment communities. For more information, please visit www.bio2008.org.

About HemoBioTech, Inc.

HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, and exclusively licensed from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S.. HemoTech is being subjected to further studies and testing to confirm and expand on these studies. At a recent meeting by the U.S. Food and Drug Administration (FDA) for blood substitutes, the FDA indicated the need for a new generation of hemoglobin based blood substitutes for development and the Adenosine-GSH approach of HemoBioTech was cited. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions.

HemoBioTech received an exclusive worldwide license from the Texas Tech University System for a new technology that addresses the safety of animal-derived products for human use in pharmaceutical, cosmetic and other industries. This new technology acts to prevent the spread of transmissible spongiform encephalopathies (TSE), also know as prions or mad cow disease, as well as viruses. The FDA strictly regulates medicinal products and cosmetics that contain ingredients from animals, particularly of bovine origin. The technology is being used in the manufacturing of HemoBioTech’s lead product HemoTech, potentially the first viable substitute for human blood. HemoTech is composed of chemically modified bovine hemoglobin.

The new purification technology, called “Orthogonal Method for the Removal of Transmissible Spongiform Encephalopathy Agents from Biological Fluids,” allows robust and reliable elimination of infectious agents, such as prions and viruses from the final product, using independent clearance steps, inactivation and removal. This is a critical purification process in enhancing the safety that is needed for approval to sell such products. The market for pharmaceutical and cosmetic products for human use derived from animals is in excess of $7 billion.

Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information contact, Dr. Arthur Bollon at: 972-455-8955 or arthurb@flash.net or visit our website at: http://www.hemobiotech.com.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech’s Annual Report on Form 10-K for the year ending December 31, 2007, as amended, and HemoBioTech’s other reports filed with the Securities and Exchange Commission.

HemoBioTech, Inc.
Arthur P. Bollon, PhD, 972-455-8950
Chairman & CEO
abollon@hemobiotech.com
or
The Investor Relations Group, Inc.
212-825-3210
Investor Relations:
Christine Berni / Conrad F. Mir
christine@investorrelationsgroup.com
conrad@investorrelationsgroup.com
or
Media:
Hayden Lynch / Janet Vasquez
hayden@investorrelationsgroup.com
janet@investorrelationsgroup.com